Small Molecule Combination Therapies Are Being Investigated to Increase Response Rates Researchers agree that now is a crucial time to be involved in hepatitis C virus (HCV) research. “Current ...
The FDA is notifying health-care professionals about potential dangerous drug interactions between the hepatitis C virus (HCV) protease inhibitor boceprevir (Victrelis, Merck) and certain anti-HIV ...
AbbVie may have an edge over Gilead in the race to bring a faster-acting, all-oral hepatitis C cure to market, but it’s a slight one. Yesterday the drugmaker presented detailed Phase-III data for its ...
"In patients with chronic infection with [HCV] genotype 1 who do not have a sustained response to therapy with peginterferon–ribavirin, outcomes after retreatment are suboptimal," write Bruce R. Bacon ...
HANGZHOU, China & RESEARCH TRIANGLE PARK, NC & SAN FRANCISCO--(BUSINESS WIRE)--Ascletis and Presidio announced today that they have entered into an exclusive licensing agreement for Presidio’s ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results